- Home
- GAME vs FGEN Comparison
GAME vs FGEN Comparison
Compare GAME & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- FGEN
- Stock Information
- Founded
- GAME 2011
- FGEN 1993
- Country
- GAME United States
- FGEN United States
- Employees
- GAME N/A
- FGEN N/A
- Industry
- GAME
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- FGEN Health Care
- Exchange
- GAME Nasdaq
- FGEN Nasdaq
- Market Cap
- GAME 27.2M
- FGEN 33.5M
- IPO Year
- GAME 2009
- FGEN 2014
- Fundamental
- Price
- GAME $1.03
- FGEN $5.57
- Analyst Decision
- GAME Strong Buy
- FGEN Strong Buy
- Analyst Count
- GAME 3
- FGEN 1
- Target Price
- GAME $3.67
- FGEN $250.00
- AVG Volume (30 Days)
- GAME 529.3K
- FGEN 60.6K
- Earning Date
- GAME 08-13-2025
- FGEN 08-05-2025
- Dividend Yield
- GAME N/A
- FGEN N/A
- EPS Growth
- GAME N/A
- FGEN N/A
- EPS
- GAME N/A
- FGEN N/A
- Revenue
- GAME $99,579,536.00
- FGEN $6,996,000.00
- Revenue This Year
- GAME $6.08
- FGEN N/A
- Revenue Next Year
- GAME $21.94
- FGEN N/A
- P/E Ratio
- GAME N/A
- FGEN N/A
- Revenue Growth
- GAME 77.06
- FGEN N/A
- 52 Week Low
- GAME $0.50
- FGEN $4.50
- 52 Week High
- GAME $1.37
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- GAME 66.10
- FGEN 37.76
- Support Level
- GAME $0.73
- FGEN $5.37
- Resistance Level
- GAME $0.97
- FGEN $5.73
- Average True Range (ATR)
- GAME 0.07
- FGEN 0.48
- MACD
- GAME 0.02
- FGEN 0.02
- Stochastic Oscillator
- GAME 85.69
- FGEN 28.78
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.